logo/base Created with Sketch.

EASL-EASD-EASO Clinical Practice Guidelines
- Update 2024 -

Prise en charge de la maladie hépatique stéatosique associée à un dysfonctionnement métabolique (MASLD)


Recommendations related to FibroScan®

These new EASL-EASD-EASO guidelines on the management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) recommend VCTE™ to measure liver stiffness with the specific cut-off value of 8 kPa in the stepwise strategy for non-invasive assessment of the risk for advanced fibrosis. 

Key takeways

This new joint EASL-EASD-EASO Clinical Practice Guidelines provides an update on definitions, prevention, screening, diagnosis and treatment for MASLD.

It’s essential to identify liver steatosis, a key feature of MASLD, that should lead to assessing advanced liver fibrosis — a predictor of liver-related outcomes.


  • Given the advancements in treatment options, it’s crucial to identify at-risk individuals with MASLD early. With these tools at our disposal, we can proactively influence the course of the disease, and potentially prevent significant clinical events.


  • To identify MASLD cases with liver fibrosis, using non-invasive tests should be applied. Focus on individuals who have cardiometabolic risk factors, abnormal liver enzymes, and/or radiological signs of hepatic steatosis—especially if they also have type 2 diabetes (T2D) or obesity with other metabolic risk factors.


  • Detecting fibrosis early and managing it appropriately can help prevent progression to cirrhosis and its related complications and may justify screening in at-risk populations.


  • A stepwise approach using the score FIB-4 and, sequentially, VCTE™ (Vibration Controlled Transient Elastography) or alternative test, is suitable to rule-out/in advanced fibrosis.


  • Adults with non-cirrhotic MASH and significant liver fibrosis (stage ≥2) should be considered for a MASH-targeted treatment with Resmetirom.


EASL-EASD-EASO Clinical Practice Guidelines – Update 2024